A recent CMS rule on genome sequencing could negatively impact oncologists and clinical researchers who use non-FDA approved next generation sequencing.
More competition in a drug space is thought to reduce the cost of those drugs; however, a recent study demonstrated that this may not be true with cancer drugs.
A recent research letter in JAMA Oncology found that a significant proportion of oncologists were not prepared to transition to MACRA.
Recent research from the American Cancer Society highlighted the major modifiable risk factors that lead to many cancer types.
A recent study in JAMA Oncology examined 7 oncology centers to determine the characteristics driving high value care.
The number of newly diagnosed cancer patients without health insurance declined by one-third in 2014, which is likely an effect of the Affordable Care Act, a small study suggests.
The FDA and the American Society of Clinical Oncology (ASCO) will be convening a joint workshop November 6, 2017, with the goal of improving the evidence base for treating the geriatric oncology population.
A presentation at the Association of Community Cancer Centers National Oncology Conference cited data showing that a lay navigator program helped reduce cancer care costs in a health system.
A study found that patients receiving cancer treatment who have a preexisting psychiatric condition incur over 200% more in treatment costs.
With limited success and skyrocketing costs, it could be time for the United States to take a hard look at the societal impact of current cancer therapy coverage practices. Countries like the United Kingdom and Sweden could provide a starting point for developing unique and innovative coverage decision-making models.